Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors

Area of Science:

• Immunology
• Cancer Biology
• Molecular Biology

Background:

• Transporter for antigen presentation 1 (TAP1) is crucial for presenting tumor antigens to MHC class I molecules.
• Lack of TAP1 expression on tumor cells can impact T-cell-dependent anti-tumor immunity.
• Tumorigenicity and immune evasion are critical aspects of cancer progression.

Purpose of the Study:

• To investigate the role of TAP1 expression in tumor cell immunogenicity and rejection.
• To determine the effect of TAP1 deficiency on tumor growth and T-cell responses.
• To elucidate the mechanisms by which tumor cells may evade immune surveillance.

Main Methods:

• Establishment of TAP1-expressing (TAP1(+)) and TAP1-deficient (TAP1(-)) tumor cell lines using ras-transformed NIH3T3 fibroblasts.
• Assessment of tumor growth and tumorigenicity in immunocompetent and T-cell-deficient mice.
• Evaluation of tumor rejection in previously immunized mice challenged with TAP1(+) or TAP1(-) tumor cells.
• Analysis of CD8(+) T cell infiltration and IFN-gamma production in mixed tumor/lymphocyte cultures.

Main Results:

• Impaired TAP1 expression increased tumor cell tumorigenicity in immunocompetent mice.
• TAP1 expression was not essential for generating tumor immunity but enhanced rejection of established tumors.
• CD8(+) T cells were required for the rejection of both TAP1(+) and TAP1(-) tumors.
• TAP1 expression on tumor cells significantly increased IFN-gamma production by antigen-specific T cells from immunized mice.

Conclusions:

• The lack of TAP1 expression does not alter the fundamental immunogenicity of tumor cells.
• Tumor cells with impaired TAP1 expression may escape T-cell recognition during the effector phase of the immune response.
• Targeting TAP1 pathways could be a strategy to enhance anti-tumor immunity and overcome immune evasion.